Bank of New York Mellon’s Rein Therapeutics RNTX Stock Holding History

Bank of New York Mellon’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,979	Closed	-$155K	–	4290
2019 Q1	$155K	Buy	+3,979	New	+$124K	﹤0.01%	3934
2017 Q4	–	Sell	-501	Closed	-$135K	–	4408
2017 Q3	$135K	Buy	+501	New	+$126K	﹤0.01%	3948

Other funds holding RNTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Bank of New York Mellon's RNTX Position: Q2 2019 in Review

Bank of New York Mellon sold out of Rein Therapeutics (RNTX) in Q2 2019, closing a stake of 3,979 shares — an estimated $155K sold.

Bank of New York Mellon first reported a position in RNTX in Q3 2017 and held it in 2 quarters. The position peaked at $155K in Q1 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q2 2019.

Bank of New York Mellon reported no remaining Rein Therapeutics position as of Q2 2019 after selling out during the quarter.
Bank of New York Mellon sold 3,979 Rein Therapeutics shares in Q2 2019, an estimated $155K.
Bank of New York Mellon first reported a position in Rein Therapeutics in Q3 2017 and held it in 2 quarters.
Bank of New York Mellon's Rein Therapeutics position peaked at $155K in Q1 2019.
22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2019.

Based on Bank of New York Mellon's 13F filing for Q2 2019, filed 12 Aug 2019.